Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS:
Galectin-1 was overexpressed in the majority of malignant CMT cases in tumor cells and stroma. Its expression in malignant tumor cells was associated with smaller-sized tumours. Distant metastases presented a strong intensity of galectin-1 and reduced galectin-3 expression, while the opposite was observed in circulating tumor cells. Interestingly intravascular tumor cells presented galectin-3 up-regulation at the mRNA level. Double-labelling further made it clear that galectin-3 and galectin-1 expression did not overlap in normal-adjacent mammary and CMT cells. CONCLUSION: Taken together, our data suggest that malignant CMT cell sub-populations have alternating expression of galectin-1 or -3. This might confer survival advantage to tumour cells in different phases of tumour progression.
|
Authors | Joana T DE Oliveira, Augusto J DE Matos, Rita Barros, Cláudia Ribeiro, Asaf Chen, Venceslau Hespanhol, Gerard R Rutteman, Fátima Gärtner |
Journal | Anticancer research
(Anticancer Res)
Vol. 34
Issue 5
Pg. 2211-21
(May 2014)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 24778023
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Galectin 1
- Galectin 3
- RNA, Messenger
|
Topics |
- Animals
- Disease Progression
- Dog Diseases
(metabolism, pathology)
- Dogs
- Female
- Galectin 1
(biosynthesis)
- Galectin 3
(biosynthesis)
- Immunohistochemistry
- Mammary Neoplasms, Animal
(metabolism, pathology)
- RNA, Messenger
(analysis)
|